Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Keros Therapeutics (KROS) Shares Outstanding (Weighted Average) (2019 - 2025)

Keros Therapeutics' Shares Outstanding (Weighted Average) history spans 7 years, with the latest figure at $37.2 million for Q4 2025.

  • For Q4 2025, Shares Outstanding (Weighted Average) fell 0.58% year-over-year to $37.2 million; the TTM value through Dec 2025 reached $37.2 million, down 0.58%, while the annual FY2025 figure was $37.2 million, 0.58% down from the prior year.
  • Shares Outstanding (Weighted Average) reached $37.2 million in Q4 2025 per KROS's latest filing, down from $40.6 million in the prior quarter.
  • In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $40.6 million in Q3 2025 to a low of $23.2 million in Q1 2021.
  • Average Shares Outstanding (Weighted Average) over 5 years is $30.7 million, with a median of $29.5 million recorded in 2023.
  • Peak YoY movement for Shares Outstanding (Weighted Average): skyrocketed 835.16% in 2021, then decreased 0.58% in 2025.
  • A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $23.3 million in 2021, then rose by 8.17% to $25.2 million in 2022, then grew by 16.66% to $29.4 million in 2023, then increased by 27.14% to $37.4 million in 2024, then fell by 0.58% to $37.2 million in 2025.
  • Per Business Quant, the three most recent readings for KROS's Shares Outstanding (Weighted Average) are $37.2 million (Q4 2025), $40.6 million (Q3 2025), and $40.6 million (Q2 2025).